To address the current challenges in oncology drug development, Meliora believes that there needs to be a fundamentally new approach to cancer drug development.
Instead of relying on short-form proxies of cell function, AnchorOmics enables a digitized language that captures the full complexity of cellular function.
The underlying unit of this language is our proprietary molecular fingerprint. This fingerprint captures the impact of a therapeutic agent on cellular function as represented by the transcriptome, methylome, proteome, morphological state, and more. We use advanced machine learning techniques to generate each perturbation’s fingerprint, and locate that fingerprint in our atlas, thus mapping an anti-cancer drug’s mechanisms of action. Fundamentally, AnchorOmics allows Meliora to combine insights from a wide range of modalities into a single vector space atlas.